Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
09 Marzo 2015 - 9:22PM
Access Wire
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015
/ Cell Source, Inc. (OTCQB:CLCS) ("Cell Source") an
immunotherapy and regenerative medicine company, announced today
its President and CEO, Itamar Shimrat, will present at the Roth
Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point,
California.
The Roth Capital Conference is among the premier annual
micro-cap conferences in the United States. The conference is an
exclusive gathering of the "Who's who" of the micro-cap space, with
a lineup of industry leaders, standout companies and cutting edge
speakers and panelists.
For further information, please visit
www.cell-source.com or contact Itamar Shimrat, President &
CEO (646) 416-7896.
About The Roth Conference
Roth Capital is an investment banking firm dedicated to the
small-cap public market. Since its inception in 1984, ROTH has been
an innovator in this market. Headquartered in Newport Beach, CA,
Roth has regional offices in Boston, Chicago, Larkspur, Los
Angeles, New York and San Diego as well as Hong Kong. Roth is
hosting its 27th annual micro-cap Conference. This
invitation-only event attracts hundreds of high net worth investors
and financial leaders. The Conference will be a unique gathering
featuring the "Who's who" of the micro-cap investment world.
About Cell Source, Inc.
Cell Source is an immunotherapy and regenerative medicine
company whose primary breakthrough is the regulation of immune
tolerance. In preclinical studies Cell Source's therapies have
demonstrated the ability to directly address a number of severe
medical conditions including blood cancers such as non-Hodgkins
lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Cell
Source's organ regeneration platform holds the potential to repair
organs and to grow entire organs inside the patient's body. Growing
or regenerating organs and using cell therapy to tolerize the
immune system can each revolutionize the treatment of numerous
severe diseases that today kill hundreds of thousands of patients
annually.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION ACT OF 1995
With the exception of historical
information, the matters discussed in this news release
are forward-looking statements that involve
a number of risks and uncertainties. The actual future
results of Cell Source could differ significantly from those
statements. Factors that could cause actual results to
differ materially include risks and uncertainties such
as the inability to finance the
company's operations, inability to hire and retain
qualified personnel, and changes in the general economic climate.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential" or
"continue," the negative of such terms, or other comparable
terminology. These statements are only
predictions. Although we believe that the expectations
reflected in the forward-looking statements are
reasonable, such statements should not be regarded as a
representation by Cell Source, or any other person, that such
forward-looking statements will be achieved. We undertake no duty
to update any of the forward-looking statements, whether as a
result of new information, future events or otherwise. In light of
the foregoing, readers are cautioned not to place undue reliance on
such forward-looking statements. This release does not
constitute an offer to sell or a solicitation of offers to buy any
securities of any entity.
SOURCE: Cell Source, Inc.
Cell Source (CE) (USOTC:CLCS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cell Source (CE) (USOTC:CLCS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024